Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas

被引:3
|
作者
Milewska, Gabriela
Ponikwicka-Tyszko, Donata [1 ]
Bernaczyk, Piotr [2 ]
Lupu, Oana
Szamatowicz, Michal
Sztachelska, Maria [1 ]
Pilaszewicz-Puza, Agata [2 ]
Koda, Mariusz [3 ]
Bielawski, Tomasz [1 ]
Zbucka-Kretowska, Monika
Pawelczyk, Adam [4 ]
Tomaszewski, Jakub [5 ]
Li, Xiangdong [6 ]
Huhtaniemi, Ilpo [1 ,7 ,8 ]
Wolczynski, Slawomir [1 ]
Rahman, Nafis A. [9 ]
机构
[1] Med Univ Bialystok, Dept Reprod & Gynecol Endocrinol, Bialystok, Poland
[2] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Biol & Pathol Human Reprod, Olsztyn, Poland
[3] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland
[4] Med Univ Bialystok, Dept Gen Pathomorphol, Bialystok, Poland
[5] Poznan Univ Med Sci, Dept Gen Vasc & Transplant Surg, Div Gen & Transplant Surg, Poznan, Poland
[6] Tomaszewski Med Ctr Obstet & Gynecol, Bialystok, Poland
[7] China Agr Univ, State Key Lab Agrobiotechnol, Beijing, Peoples R China
[8] Imperial Coll London, Inst Reprod & Dev Biol, Dept Metab Digest & Reprod, London, England
[9] Univ Turku, Inst Biomed, Turku 20520, Finland
基金
芬兰科学院;
关键词
Leiomyoma; progesterone; selective progesterone receptor modulator; extracellular matrix; growth factors; COLLAGEN MESSENGER-RNA; P38; MAPK; BETA; PATHOGENESIS; PATHWAYS; FIBRONECTIN; EXPRESSION; TARGET;
D O I
10.1016/j.fertnstert.2024.02.046
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the specific fi c mechanisms through which progesterone and selective progesterone receptor modulators impact the growth, synthesis, and accumulation of the extracellular matrix in uterine leiomyomas. Design: Laboratory study. Setting: Academic Research Institutions. Patients (s): This study involved reproductive-age women diagnosed with infertility associated uterine leiomyomas who underwent myomectomy either after selective progesterone receptor modulator ulipristal acetate (UA) treatment or without any pharmacological pretreatment. Control samples included healthy myometrium tissue (n = 100). Specimens were obtained from the Department of Reproduction and Gynecological Endocrinology and Biobank, Medical University of Bialystok, Poland. Interventions: Daily (5 mg/d) UA treated for 2 months (n = 100) and untreated (n = 150) patients with uterine leiomyomas or normal healthy myometrium (n = 100) tissue samples immediately after surgery were collected for transcriptional analysis and assessments. Main Outcome Measures: Progesterone-induced activation of the signaling pathways related to uterine leiomyomas extracellular matrix synthesis, deposition, and growth, as well as the expression profile fi le of progesterone receptors in uterine leiomyomas, were assessed. Results: The results indicated that progesterone activated the transforming growth factor-f3 f3 and SMAD3 signaling pathways and promoted proliferation, growth, and extracellular matrix remodeling in uterine leiomyomas by up-regulating SMAD3, transforming growth factor-f3 f3 (TGF-f3) f3 ) receptor type 1 and II, Ras homolog A, vascular endothelial growth factor, or increasing the fi brosis- related gene collagen, type I, alpha-1, and procollagen, type I, alpha-1 production. In contrast, UA had inhibitory effects on these processes. The study also showed that both nuclear and membrane progesterone receptors play distinct roles in uterine leiomyoma pathobiology. Conclusions: We showed that both nuclear and membrane progesterone receptors were relevant in the treatment of uterine leiomyomas, especially when combined with selective progesterone receptor modulators. Novel therapeutic approaches combining selective progesterone receptor modulators with or without direct and indirect extracellular matrix targeting through selected specifically fi cally TGF-3 3 and SMAD3 (SMAD3, TGF-3 3 receptor types 1 and II, Ras homolog A, vascular endothelial growth factor, collagen, type I,alpha-1) alpha-1) signaling pathways could therefore be a treatment option for uterine leiomyomas. (Fertil Steril (R) (R) 2024;122:341-51. - 51. (c) 2024 by American Society for Reproductive Medicine.) El resumen est & aacute; disponible en Espa & ntilde;ol al final del art & iacute;culo.
引用
收藏
页码:341 / 351
页数:11
相关论文
共 50 条
  • [21] Selective progesterone receptor modulators (SPRMs) for uterine fibroids
    Murji, Ally
    Whitaker, Lucy
    Chow, Tiffany L.
    Sobel, Mara L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04):
  • [22] Selective Progesterone Receptor Modulator(ulipristal acetate - a new option in the pharmacological treatment of uterine fibroids in women
    Szamatowicz, Marian
    Kotarski, Jan
    GINEKOLOGIA POLSKA, 2013, 84 (03) : 219 - 222
  • [23] Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
    Szydlowska, Iwona
    Marciniak, Aleksandra
    Nawrocka-Rutkowska, Jolanta
    Ryl, Aleksandra
    Starczewski, Andrzej
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (03)
  • [24] Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
    Szydlowska, Iwona
    Grabowska, Marta
    Nawrocka-Rutkowska, Jolanta
    Kram, Andrzej
    Piasecka, Malgorzata
    Starczewski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [25] A structural and in vitro characterization of asoprisnil:: A selective progesterone receptor modulator
    Madauss, Kevin P.
    Grygielko, Eugene T.
    Deng, Su-Jun
    Sulpizio, Anthony C.
    Stanley, Thomas B.
    Wu, Charlene
    Short, Steve A.
    Thompson, Scott K.
    Stewart, Eugene L.
    Laping, Nicholas J.
    Williams, Shawn P.
    Bray, Jeffrey D.
    MOLECULAR ENDOCRINOLOGY, 2007, 21 (05) : 1066 - 1081
  • [26] Asoprisnil, a novel selective progesterone receptor modulator (SPRM), controls abnormal uterine bleeding in subjects with leiomyomata
    Chwalisz, K
    Larsen, L
    Mattia-Goldberg, C
    McCrary, K
    Edmonds, A
    Human Reproduction, 2005, : 556 - 556
  • [27] Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies
    Wagenfeld, Andrea
    Saunders, Philippa T. K.
    Whitaker, Lucy
    Critchley, Hilary O. D.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (09) : 1045 - 1054
  • [28] REGULATION OF UTERINE AND VAGINAL PROGESTERONE RECEPTOR LEVELS BY ESTROGEN ACTION
    ALLEN, TC
    LEAVITT, WW
    FEDERATION PROCEEDINGS, 1976, 35 (03) : 798 - 798
  • [29] 90 YEARS OF PROGESTERONE Molecular mechanisms of progesterone receptor action on the breast cancer genome
    Beato, Miguel
    Wright, Roni H. G.
    Le Dily, Francois
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2020, 65 (01) : T65 - T79
  • [30] The potential of selective progesterone receptor modulators for the treatment of uterine fibroids
    Bestel, Elke
    Donnez, Jacques
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (01) : 79 - 92